- Home
- CDTX vs ITOS Comparison
CDTX vs ITOS Comparison
Compare CDTX & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTX
- ITOS
- Stock Information
- Founded
- CDTX 2012
- ITOS 2011
- Country
- CDTX United States
- ITOS United States
- Employees
- CDTX N/A
- ITOS N/A
- Industry
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CDTX Health Care
- ITOS Health Care
- Exchange
- CDTX Nasdaq
- ITOS Nasdaq
- Market Cap
- CDTX 242.5M
- ITOS 283.9M
- IPO Year
- CDTX 2015
- ITOS 2020
- Fundamental
- Price
- CDTX $20.53
- ITOS $7.26
- Analyst Decision
- CDTX Strong Buy
- ITOS Strong Buy
- Analyst Count
- CDTX 6
- ITOS 3
- Target Price
- CDTX $32.20
- ITOS $25.33
- AVG Volume (30 Days)
- CDTX 86.5K
- ITOS 442.9K
- Earning Date
- CDTX 11-07-2024
- ITOS 11-12-2024
- Dividend Yield
- CDTX N/A
- ITOS N/A
- EPS Growth
- CDTX N/A
- ITOS N/A
- EPS
- CDTX N/A
- ITOS N/A
- Revenue
- CDTX $44,653,000.00
- ITOS $35,000,000.00
- Revenue This Year
- CDTX N/A
- ITOS $271.18
- Revenue Next Year
- CDTX N/A
- ITOS N/A
- P/E Ratio
- CDTX N/A
- ITOS N/A
- Revenue Growth
- CDTX 44.48
- ITOS N/A
- 52 Week Low
- CDTX $10.00
- ITOS $7.13
- 52 Week High
- CDTX $24.99
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- CDTX 55.06
- ITOS 30.40
- Support Level
- CDTX $21.15
- ITOS $7.44
- Resistance Level
- CDTX $24.99
- ITOS $7.96
- Average True Range (ATR)
- CDTX 2.10
- ITOS 0.37
- MACD
- CDTX -0.15
- ITOS -0.04
- Stochastic Oscillator
- CDTX 41.16
- ITOS 8.41
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.